Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04376866

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma Clinical Trial

Official title:
Toripalimab in Combination With Concurrent Chemoradiotherapy for Local-regional Recurrent Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial

Clinical Trial Summary

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Clinical Trial Description

Nasopharyngeal carcinoma (NPC) is endemic in southern China, southeast Asia, and northern Africa. According to a survey from the International Agency for Research on Cancer, there were an estimated 129,079 new cases and 72,987 related deaths in 2018. Radiotherapy is the primary treatment option. Due to advances in disease management, diagnostic imaging, radiotherapy technology, and the broader application of systemic therapy, the prognosis of NPC has improved signifificantly.Nevertheless, localregional recurrence will occur in about 10% patients. Because of radiation resistance, the prognosis of re-irradiation is poor for recurrent nasopharyngeal carcinoma. Hence, there is an urgent need for novel therapies to improve survival and reduce treatment-related toxicity in recurrent NPC patients. Emerging evidence shows that PD-1 antibody is effective for treating recurrent/metastastic NPC patients. This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent chemoradiotherapy (CCRT) versus CCRT alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04376866
Study type Interventional
Source Cancer Hospital of Guangxi Medical University
Contact Song Qu, PhD
Phone 86-13607887386
Email daisyqs2002@163.com
Status Recruiting
Phase Phase 3
Start date June 28, 2020
Completion date April 2028
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06010095 - Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Phase 2
Recruiting NCT03639467 - Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma Phase 1/Phase 2
Recruiting NCT06029270 - Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase 2
Recruiting NCT03666221 - Nimotuzumab for Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05350891 - Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC Phase 2
Active, not recruiting NCT04586088 - Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure Phase 2
Active, not recruiting NCT04405622 - Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. Phase 2
Recruiting NCT06235203 - Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC Phase 3
Not yet recruiting NCT04215510 - Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT Phase 3
Recruiting NCT03930498 - Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT03907826 - PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients Phase 3
Not yet recruiting NCT05432219 - A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma N/A
Recruiting NCT04425265 - Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma N/A
Not yet recruiting NCT03689556 - Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
Not yet recruiting NCT03210389 - A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. Phase 2
Completed NCT01370070 - MK-2206 in Recurrent Nasopharyngeal Carcinoma Phase 2
Completed NCT01392235 - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) Phase 2
Not yet recruiting NCT06228079 - Adjuvant vs Surgery Only in Early-stage Recurrent NPC Phase 3
Terminated NCT04458909 - Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Phase 3
Withdrawn NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Phase 2